Print Page   |   Sign In   |   Create a Profile
News & Press: Industry News

Ex-Biomet CEO Binder is Immucor’s new chief exec

Monday, July 6, 2015   (0 Comments)
Posted by: Angela King
Share |

Immucor said it named Jeffrey Binder, who led Biomet until its $13.34 billion merger with Zimmer (NYSE:ZMH), to be its new chairman, president & CEO.

Binder replaces William Hawkins, the former Medtronic (NYSE:MDT) chief executive who took the reins at Immucor in 2011. Hawkins will assume the role of lead director on Immucor’s board, that company said.

Immucor is owned by private equity player TPG Capital.

“Immucor is an innovative market leader that is revolutionizing transfusion and transplant medicine, and I look forward to the opportunity to work with the excellent management team and employees to further capitalize on market opportunities,” Binder said in prepared remarks. “I’ve thoroughly enjoyed working with the TPG team during my tenure at Biomet, and know that together we can form another successful partnership at Immucor.”

“It was a privilege to lead the talented team at Immucor and I am very proud of what we have accomplished in our time together,” Hawkins added. “Immucor is in good hands with Jeff at the helm and I look forward to working with Jeff and the board in my new role as lead director to ensure Immucor’s continued success.”

“Jeff joins Immucor with a wealth of experience and a proven track record of success in the healthcare industry. Having worked with Jeff over the past 8 years, we believe he is 1 of the most talented executives in healthcare and is uniquely qualified to lead Immucor into its next chapter of growth. We are pleased that Jeff will also serve as a senior advisor to TPG Capital,” TPG Capital North America managing partner Todd Sisitsky said in a statement. “We are extremely grateful to Bill for his leadership of Immucor over the past 4 years. During Bill’s tenure, the company has expanded globally, entered transplant medicine, resolved the legacy FDA NOIR, introduced breakthrough molecular technologies, and built a rich pipeline of diagnostic assays and systems. We are pleased that he will remain with the company as lead director and look forward to continuing to benefit from his experience and insight.”

Source.  Mass Device.

more Calendar

Swings Fore STEM Golf Outing 2018

Boehringer-Ingelheim Industry Tour

Membership Software Powered by YourMembership  ::  Legal